Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

New Patent Strengthens AroCell's Intellectual Property Portfolio

IDL Diagnostics

AroCell AB is pleased to announce the Japanese Patent Office's confirmation of a new patent (patent application number: 2021-564698) for an innovative use of the TK1 protein in detecting and categorizing respiratory infections.

This patent, which was previously granted by the European Patent Office (EP3966568) in July 2024, signifies a major milestone for AroCell. It relates specifically to the use of serum thymidine kinase 1 (sTK1) to predict and diagnose Mycoplasma pneumonia caused by M. pneumoniae. Additionally, the TK1 protein levels can assist in determining the type of respiratory infection: if the TK1 levels are above the threshold, it indicates Mycoplasma pneumonia; if they are below the threshold, it suggests pneumonia caused by a different bacterium.

The research that supports the patent demonstrates an exciting opportunity to extend the use of our TK1 test to include respiratory infections. By strengthening the protection of our test, we facilitate further commercialization and broader use of our TK1 marker.

Contacts


Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About Thymidine Kinase 1


Thymidine Kinase 1 (TK1) is a key enzyme in DNA precursor synthesis. It is up-regulated during the S phase of the cell cycle and degraded in mitosis. Its presence in cells indicates active cell proliferation. Increased levels of TK1 in the blood can indicate abnormal cell turnover or disruption of cells in active proliferation triggered by, for example, therapeutic agents.

About AroCell


AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments


New Patent Strengthens AroCell's Intellectual Property Portfolio

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.